Contact
Please use this form to send email to PR contact of this press release:
INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO
TO:
Please use this form to send email to PR contact of this press release:
INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO
TO: